Abstracts tagged "Idiopathic Inflammatory Myopathies (IIM)"

Abstract Number: 373 • 2018 ACR/ARHP Annual Meeting
The Effect of an Intensive Controlled 6-Moth Exercise Program with Subsequent 6-Month Follow-up Period in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data
Maja Spiritovic^1,2, Sabina Oreska^2,3, Hana Storkanova^2,3, Barbora Hermankova^1,2, Petr Cesak⁴, Adela Rathouska², Katerina Kubinova^2,3, Martin Klein^2,3, Lucia Vernerova^2,3, Olga Ruzickova^2,5, Herman F Mann^2,6, Karel Pavelka^2,3, Ladislav Šenolt^2,3, Jiri Vencovsky^2,7 and Michal Tomcik^2,3, ¹Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ³Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Body Composition Laboratory, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Muscle inflammation and weakness, subsequent atrophy and permanent muscle damage in idiopathic inflammatory myopathies (IIM) lead to impaired function, reduced muscle strength, endurance and…
Abstract Number: 875 • 2018 ACR/ARHP Annual Meeting
Anti-Calreticulin Antibody – a Novel Antibody in Patients with Idiopathic Inflammatory Myopathies and Its Association with Malignancy
He Chen^1,2, Guochun Wang³ and Xin Lu⁴, ¹Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, ²Graduate School of Peking Union Medical College, Beijing, China, ³China-Japan Friendship Hospital, Beijing, China, ⁴Rheumatology, China-Japan Friendship Hospital, Beijing, China
Background/Purpose: To investigate the occurrence of anti-calreticulin antibodies (anti-CRT Abs) and evaluate its association with malignancy in patients with idiopathic inflammatory myopathies (IIM). Methods: In…
Abstract Number: 1032 • 2018 ACR/ARHP Annual Meeting
Aberrant Sarcoplasmic Expression of the Alarmin ‘High Mobility Group Box Protein 1” (HMGB1) in Patients with Idiopathic Inflammatory Myopathy
Jessica Day¹, Sophia Otto², Kathy Cash³, Preethi Eldi⁴, Pravin Hissaria⁵, Susanna Proudman⁶, John Hayball⁴ and Vidya Limaye⁷, ¹Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ²Pathology, Royal Adelaide Hospital, Adelaide, Australia, ³Muscle and Nerve Laboratory, SA Pathology, Adelaide, Australia, ⁴Experimental Therapeutics Laboratory, University of South Australia, Adelaide, Australia, ⁵Immunology, Royal Adelaide Hospital, Adelaide, Australia, ⁶Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁷Rheumatology, The Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Components of the innate immune system, such a High Mobility Group Box Protein 1 (HMGB1), may contribute to the initiation, perpetuation and resolution of…
Abstract Number: 2294 • 2018 ACR/ARHP Annual Meeting
Improving EULAR/Acr Classification Criteria for Idiopathic Inflammatory Myopathies
Kylee Dawson¹, Chester V. Oddis², Siamak Moghadam-Kia², Diane Koontz², Nicole Niemen² and Rohit Aggarwal², ¹Internal Medicine, Department of Medicine, University of Pittsburgh Medical Center Mercy Hospital, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: New 2016 EULAR/ACR classification criteria have been established for idiopathic inflammatory myopathies (IIM). The highest weighted score is associated with the presence of anti-Jo-1…
Abstract Number: 2295 • 2018 ACR/ARHP Annual Meeting
Classification of Idiopathic Inflammatory Myopathies: Assessment of 123 Patients According to 2017 Acr/EULAR Criteria Followed up By a Single Center from Turkey
Emin Oguz¹, Ezgi Sahin², Murat Erdugan¹, Bahar Artim-Esen¹, Ahmet Gül¹, Lale Ocal¹ and Murat Inanc³, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey, ³Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey
Background/Purpose: The aim of this study is to evaluate sensitivity, limitations and assessment of 2017 ACR/EULAR IIMs classification criteria (ACR/EULAR2017) in 123 patients with idiopathic…
Abstract Number: 2913 • 2018 ACR/ARHP Annual Meeting
A Draft Modified Core Domain Set for Patient-Reported Outcomes (PRO) in Patients with Idiopathic Inflammatory Myopathies (IIM): An Omeract Report
Malin Regardt^1,2, Christopher A. Mecoli^3,4,5, Jin Kyun Park^{6,7,8,9,10,11,12,13,14}, Merrilee Needham¹⁵, Ingrid De Groot¹⁶, Catherine Sarver¹⁷, Ingrid E. Lundberg¹⁸, Beverly Shea¹⁹, Marianne De Visser²⁰, Yeong Wook Song¹³, Clifton O. Bingham III²¹, Lisa Christopher-Stine^22,23,24 and Helene Alexanderson²⁵, ¹Learning, Informatics,Management and Ethics, Karolinska institutet, Stockholm, Sweden, ²Function Area Occupational Therapy and Physical Therapy, Karolinska University Hospital, Stockholm, Sweden, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, Republic of (South), ⁷Division of Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁸Department of Molecular medicine and biopharmaceutical science, Seoul National University, seoul, Korea, Republic of (South), ⁹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ¹⁰[email protected], Division of Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), ¹¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ¹²Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), ¹³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ¹⁴Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Korea, Republic of (South), ¹⁵Murdoch University, Perth, Australia, ¹⁶patient research partner, Rotterdam, Netherlands, ¹⁷patient research partner, maryland, MD, ¹⁸Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ¹⁹Bruyere Research Institute, Ottawa, ON, Canada, ²⁰Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands, ²¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²²Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD, ²³Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ²⁴Medicine and Neurology, Johns Hopkins University, Baltimore, MD, ²⁵Department of NVS, Division of Physical Therapy, Karolinska Institutet, Huddinge, Sweden
A Draft Modified Core Domain Set for Patient-Reported Outcomes (PRO) in Patients with Idiopathic Inflammatory Myopathies (IIM): An OMERACT ReportBackground/Purpose: The OMERACT Myositis special interest…
Abstract Number: 2146 • 2017 ACR/ARHP Annual Meeting
CD4+CXCR4+t Cells in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease
Kaiwen Wang¹, Jangfeng Zhao¹, Zhiwei Chen¹, Ting Li¹, Xiaoming Tan², Yu Zheng², Liyang Gu¹, Li Guo¹, Fangfang Sun¹, Haiting Wang¹, Jiajie Li¹, Xiaodong Wang¹, Gabriela Riemekasten³ and Shuang Ye⁴, ¹Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Department of Pulmonology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³University Hospital Schleswig-Holstein, Campus Lübeck, Department of Rheumatology and Clinical Immunology, Luebeck, Germany, ⁴Department of Rheumatology, Renji Hospital South Campus, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: The clinical and mechanistic relevance of peripheral CD4+CXCR4+ T cells in idiopathic inflammatory myopathy (IIM)-associated interstitial lung disease (IIM-ILD) is not known. Methods: Patients…
Abstract Number: 2154 • 2017 ACR/ARHP Annual Meeting
Efficacy of an Intensive 24-Week Physiotherapy Programme in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data from a Single-Center Controlled Study
Maja Spiritovic^1,2, Sabina Oreska¹, Hana Storkanova¹, Petr Cesak², Adela Rathouska¹, Katerina Kubinova¹, Martin Klein¹, Lucia Vernerova¹, Olga Ruzickova¹, Herman F Mann¹, Karel Pavelka¹, Ladislav Senolt¹, Jiri Vencovsky¹ and Michal Tomcik¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Involvement of musculoskeletal system (inflammation, atrophy and permanent damage to the muscle) in idiopathic inflammatory myopathies (IIM) leads to impaired function, reduced muscle strength,…
Abstract Number: 2136 • 2017 ACR/ARHP Annual Meeting
Association of HLA-DQA1*05 with the Presence of Interstitial Lung Disease Independent of Autoantibody Status in Caucasian Patients with Polymyositis and Dermatomyositis
Adam Schiffenbauer¹, Sara Faghihi-Kashani², Terrance P. O'Hanlon¹, Willy Flegel³, Sharon Adams³, Ira N. Targoff⁴, Chester V. Oddis^5,6, Rohit Aggarwal^7,8, Lisa G Rider¹, Steven R. Ytterberg⁹, Lisa Christopher-Stine¹⁰, Sonye K. Danoff¹¹, Paul F. Dellaripa^12,13, Ejaz Shamim¹⁴, Andrew Mammen¹⁵ and Frederick W Miller¹⁶, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, ³Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, ⁴VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Rheumatology/Clinical Immunology, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁸Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹Rheumatology, Mayo Clinic, Rochester, MN, ¹⁰Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, ¹²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ¹³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ¹⁴9. Department of Neurology, Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, ¹⁵Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ¹⁶Clinical Research Branch / Environmental Autoimmunity Group, NIH, Bethesda, MD
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication and a major contributor to mortality and morbidity in polymyositis and dermatomyositis (PM/DM). Prior studies have…
Abstract Number: 269 • 2016 ACR/ARHP Annual Meeting
The Immunoproteasomes Are Essential for Maintaining Myokine Production and MHC Class I Expression in Idiopathic Inflammatory Myopathies
Salyan Bhattarai¹, Khetam Ghannam¹, Sabine Krause², Olivier Benveniste³, Andreas Marg⁴, Gerjan de Bruin⁵, Bo-Tao Xin⁵, Herman S Overkleeft⁶, Simone Spuler⁷, Werner Stenzel⁷ and Eugen Feist⁷, ¹Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Friedrich Baur Institute, Ludwig Maximilians University, Munich, Germany, ³Pitié-Salpêtrière University Hospital, Paris, France, ⁴Muscle Research Unit, Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁵Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands, ⁶Leiden University, Leiden, Netherlands, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are muscle diseases, characterized by inflammatory infiltration and increased expression of MHC class I molecules on myofibers. Immunoproteasome, as a…
Abstract Number: 278 • 2016 ACR/ARHP Annual Meeting
Expression of Anti-Microbial Peptide LL-37 Correlates to the Activation of Type I Interferon Pathway in Patients with Idiopathic Inflammatory Myopathies
Xin Lu¹, Quan Tang², Monica Lindh³, Birgitta Agerberth⁴, Maryam Dastmalchi⁵, Ingrid E. Lundberg⁶ and Cecilia Wick⁷, ¹Rheumatology, China-Japan Friendship Hospital, Beijing, China, ²Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden, ⁴Department of Medical Biochemistry and Biophysics, Chemistry I, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ⁵Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden, ⁶Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are systemic autoimmune diseases whose pathogenesis remain unclear. The type I interferon system has recently been suggested to have…
Abstract Number: 284 • 2016 ACR/ARHP Annual Meeting
Gene-Environmental Interaction of HLA-DRB1*03:01 and Smoking for the Development of Anti-Jo-1 Autoantibodies in Idiopathic Inflammatory Myopathies: A UK Study
Nicolas Pipis¹, Simon Rothwell¹, Robert Cooper², Lucy R Wedderburn³, Neil J. McHugh⁴, Zoe Betteridge⁴, Janine Lamb⁵ and Hector Chinoy^1,6, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²Department of Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ³Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁴Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁵Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and extramuscular manifestations. The most common autoantibody…
Abstract Number: 1367 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes and Their Predictors in Patients with Juvenile Idiopathic Inflammatory Myopathies of Adult Age: A Referral Population Study
Sam Serafi¹, Vladislav Tsaltskan², Anna Yakovleva³, Heidi Sami¹, Frederick W. Miller⁴, Rodolfo Curiel¹, Olcay Y. Jones^1,5 and Lisa G. Rider^1,4, ¹Rheumatology, George Washington University, Washington, DC, ²Internal Medicine, George Washington University, Washington, DC, ³Department of Microbiology, Immunology, and Tropical Medicine., George Washington University, Washington, DC, ⁴Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ⁵Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: To investigate the long-term outcomes and prognostic factors for pts with juvenile-onset idiopathic inflammatory myopathies (JIIM) who are currently adults. Methods: Adults with JIIM…
Abstract Number: 285 • 2015 ACR/ARHP Annual Meeting
Tobacco Smoking in Different Racial Groups Is Differentially Associated with the Development of Myositis Autoantibodies and Interstitial Lung Disease in the Idiopathic Inflammatory Myopathies
Adam Schiffenbauer¹, Natalie Smith², Lisa G Rider¹ and Frederick W. Miller³, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Statistics, Purdue University, Allison Park, PA, ³Clinical Research Branch / Environmental Autoimmunity Group, NIH, Bethesda, MD
Background/Purpose: Smoking has been found to be a risk or protective factor in certain autoimmune diseases. Yet, its role in the idiopathic inflammatory myopathies (IIM)…
Abstract Number: 290 • 2015 ACR/ARHP Annual Meeting
Cancer and Necrotizing Immune Mopathy: High Incidence in Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive and Seronegative Patients but Not in Anti-Single Recognition Particle Positive Patients
Yves Allenbach¹, Jeremy Kaeren¹, Nicolas Champtiaux¹, Yoland Schoindre¹, Kuberaka Mariampillai¹, Aude Rigolet¹, Lucile Musset², Jean- Luc Charuel², Anthony Behin³, Bruno Eymard⁴, Pascal Laforet⁵, Tanya Stojkovic⁵, Olivier Boyer⁶, Baptiste Hervier⁷ and Olivier Benveniste¹, ¹Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ²Laboratoire d'immunochimie, Pitié- Salpêtrière, Paris, France, ³Institute of Myology, Pitie-Salpetriere Hospital, Paris, France, ⁴Department of Neurology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ⁵Department of Neurology, Myology Institute, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, ⁶Immunology, Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ⁷Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, Paris, France
Background/Purpose: Twenty percent of inflammatory myopathy are associated with a synchronous cancer occurring ±3 years around the diagnosis. Malignancy is a major cause of mortality…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].